January 26, 2006 13:00 ET

Nymox NicAlert™ Saliva Data to be Presented at International Meeting of Nicotine and Tobacco Experts

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 26, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the results from the successfully completed clinical studies of the Company's saliva version of the NicAlert™ test for tobacco exposure will be presented on February 18, 2006 at the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) in Orlando, FL. The Society currently has over a thousand members, including many of the top experts on nicotine and tobacco from over 20 countries around the world.

The presentation of the NicAlert™ saliva study results will be made by Dr. Norman J. Montalto, one of the principal investigators in the studies. Dr. Montalto is a clinical expert in the field of tobacco use and dependency, and is Professor in the Department of Family Medicine at West Virginia University in Charleston, WV, and Director of the Freedom from Tobacco Use Program in Charleston.

The studies were independently undertaken in family practice medical clinics under the supervision of principal investigators, Dr. Montalto and Dr. Wayne O. Wells to assess the accuracy and utility of the saliva test. Dr. Wells is Principal Investigator and Medical Director of Clinical Research Centers of Tennessee in Lebanon, TN, with expertise in tobacco dependency.

The studies clearly showed the accuracy and usefulness of the NicAlert™ saliva test in the general medical setting. The full results from the studies will be published in the medical literature.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin